Perceive Biotherapeutics, a biotech company pioneering novel technologies and therapeutics in ophthalmology, today announced the closing of a $78M Series B funding round led by Johnson & Johnson Innovation - JJDC, Inc.(JJDC), joining existing Series A investor Deerfield Management and new investors Braidwell LP, the Retinal Degeneration Fund, and Catalio Capital Management, LP.

Perceive Biotherapeutics is advancing a deep and diversified pipeline of targets and treatment modalities in multiple therapeutic verticals, with lead pipeline programs in ophthalmology. Perceive was founded on compelling research elucidating two novel protective biologies for treating retinal blindness, developed from foundational collaborations in genetic science and target validation.